ATE423547T1 - N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform - Google Patents

N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Info

Publication number
ATE423547T1
ATE423547T1 AT97945550T AT97945550T ATE423547T1 AT E423547 T1 ATE423547 T1 AT E423547T1 AT 97945550 T AT97945550 T AT 97945550T AT 97945550 T AT97945550 T AT 97945550T AT E423547 T1 ATE423547 T1 AT E423547T1
Authority
AT
Austria
Prior art keywords
phosphatidylethanolamine
acyl
active ingredient
liposome form
ingredient dosage
Prior art date
Application number
AT97945550T
Other languages
English (en)
Inventor
Paul Meers
Tong Shangguan
Shaukat Ali
Andrew Janoff
Charles Pak
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Application granted granted Critical
Publication of ATE423547T1 publication Critical patent/ATE423547T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT97945550T 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform ATE423547T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2855796P 1996-10-15 1996-10-15

Publications (1)

Publication Number Publication Date
ATE423547T1 true ATE423547T1 (de) 2009-03-15

Family

ID=21844115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97945550T ATE423547T1 (de) 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Country Status (13)

Country Link
US (2) US6120797A (de)
EP (1) EP0966267B1 (de)
AT (1) ATE423547T1 (de)
AU (1) AU725257B2 (de)
CA (1) CA2276269C (de)
DE (1) DE69739277D1 (de)
ES (1) ES2321769T3 (de)
HU (1) HUP0000522A3 (de)
IL (1) IL130822A (de)
NO (1) NO993257L (de)
NZ (2) NZ336538A (de)
SK (1) SK283760B6 (de)
WO (1) WO1998016199A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198854B1 (de) 1997-09-18 2011-11-30 Pacira Pharmaceuticals, Inc. Retardierte Freisetzung Liposomaler Anesthetischer Zusammensetzungen
ATE554748T1 (de) 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69940735D1 (de) 1998-07-17 2009-05-28 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
EP1105096B1 (de) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injizierbare wässerige propofoldispersionen
EP1419252A2 (de) * 2001-04-04 2004-05-19 Merrion Research I Limited Genetische analyse der peyer'schen plaques und m zellen und verfahren und zusammensetzungen zur targeting der peyer'schen plaques und m zellen
AU2002322024B2 (en) * 2001-05-31 2008-05-08 Pacira Pharmaceuticals, Inc. Encapsulation of nanosuspensions in liposomes and microspheres
CA2478066C (en) * 2001-12-04 2009-09-08 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
US20060058249A1 (en) * 2002-01-09 2006-03-16 Shangguan Tong Efficient nucleic acid encapsulation into medium sized liposomes
WO2003059279A2 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation under mild conditions
US20090191259A1 (en) * 2002-01-09 2009-07-30 Transave, Inc. Efficient liposomal encapsulation
WO2003068210A1 (en) * 2002-02-12 2003-08-21 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
EP1536843B1 (de) * 2002-07-02 2010-12-22 Board Of Regents, The University Of Texas System Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
WO2005011708A1 (en) * 2003-07-31 2005-02-10 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
ITMI20041280A1 (it) * 2004-06-24 2004-09-24 Hunza Di Pistolesi Elvira & C Preparazione farmaceutiche dietetiche e-o cosmetiche per il trattamento dell'obesita' dell'alopecia della cellulite e dell'invecchiamento cutaneo
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2006332340B2 (en) 2005-12-30 2013-09-26 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
WO2008030818A2 (en) * 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
KR20110033118A (ko) * 2008-07-08 2011-03-30 케미 에스.피.에이. Ｎ-아실-포스파티딜-에탄올아민의 생산 방법
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
JP5805634B2 (ja) 2009-06-08 2015-11-04 アムニクス オペレーティング インコーポレイテッド 成長ホルモンポリペプチド並びにその作成及び使用方法
US9642817B2 (en) 2009-08-27 2017-05-09 Technion Research & Development Foundation Limited Liposomal compositions and uses of same
CA2778678A1 (en) 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Improved neurturin molecules
US20130273561A1 (en) * 2010-10-29 2013-10-17 The Governing Council Of The University Of Toronto Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
KR102242875B1 (ko) 2014-03-25 2021-04-20 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 리프리젠티드 바이 더 세크리터리 오브 더 아미 모노포스포릴 지질 a (mpla)-함유 리포솜 조성물 및 사포닌을 포함하는 무독성 아주반트 제제
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
WO2018071679A1 (en) * 2016-10-13 2018-04-19 Carnot, Llc N-acylethanolamide derivatives and uses thereof
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
IL292991A (en) 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
KR20250021608A (ko) 2017-05-08 2025-02-13 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 융합을 촉진시키기 위한 조성물 및 그의 용도
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
JP2022513040A (ja) 2018-11-14 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド コンパートメント特異的カーゴ送達のための組成物および方法
CA3182372A1 (en) 2020-06-25 2021-12-30 Amunix Pharmaceuticals, Inc. Her-2 targeted bispecific compositions and methods for making and using the same
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4415713A4 (de) 2021-10-14 2025-08-06 Pacira Pharmaceuticals Inc Bupivacain-multivesikuläre liposomformulierungen und verwendungen davon
US20250177516A1 (en) 2022-03-14 2025-06-05 Pfizer Inc. Methods for producing an adjuvant
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents

Also Published As

Publication number Publication date
NZ514133A (en) 2001-09-28
US6120797A (en) 2000-09-19
SK283760B6 (sk) 2004-01-08
AU4672397A (en) 1998-05-11
IL130822A (en) 2005-12-18
NO993257L (no) 1999-07-28
WO1998016199A1 (en) 1998-04-23
CA2276269A1 (en) 1998-04-23
EP0966267A4 (de) 2006-02-01
AU725257B2 (en) 2000-10-12
CA2276269C (en) 2008-09-02
HUP0000522A1 (hu) 2000-09-28
NO993257D0 (no) 1999-06-30
NZ336538A (en) 2001-11-30
DE69739277D1 (de) 2009-04-09
IL130822A0 (en) 2001-07-24
ES2321769T3 (es) 2009-06-10
EP0966267A1 (de) 1999-12-29
HUP0000522A3 (en) 2000-10-30
US6294191B1 (en) 2001-09-25
EP0966267B1 (de) 2009-02-25
SK99399A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
ATE423547T1 (de) N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
IL140710A0 (en) Pulmonary delivery of active agents
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
FI954990A0 (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
SE9704546D0 (sv) Novel compounds
DE60138566D1 (en) Selbstformende thermodynamisch stabile liposome
IL128801A0 (en) Combination of no synthase inhibitors and traps of reactive forms of oxygen
DE69905170T2 (de) Thiazolopyrimidinderivate
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
TR199901077A2 (en) �spen�iyari form�lasyonlar.
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
ES2108698T3 (es) Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ES2071995T3 (es) Composicion para la activacion de macrofagia.
ATE345778T1 (de) (ester)-lysolecithine in liposomen
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
BR9714353A (pt) Sulfonil-benzazolonas
GB9818445D0 (en) Medicaments
MX9705592A (es) Composiciones farmaceuticas que contienen corticosteroides y preparacion de las mismas.
ITRM980392A0 (it) Plasmide per la produzione di peptidi antimicrobici in batteri ricombinati

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties